These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

394 related articles for article (PubMed ID: 28526721)

  • 1. Health Care Resource Utilization and Associated Costs Among Metastatic Cutaneous Melanoma Patients Treated with Ipilimumab (INTUITION Study).
    McArthur GA; Mohr P; Ascierto PA; Arance A; Banos Hernaez A; Kaskel P; Weichenthal M; Shinde R; Stevinson K
    Oncologist; 2017 Aug; 22(8):951-962. PubMed ID: 28526721
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Real-world healthcare costs of ipilimumab in patients with advanced cutaneous melanoma in The Netherlands.
    Franken MG; Leeneman B; Jochems A; Schouwenburg MG; Aarts MJB; van Akkooi ACJ; van den Berkmortel FWPJ; van den Eertwegh AJM; de Groot JWB; van der Hoeven KJM; Hospers GAP; Kapiteijn E; Koornstra R; Kruit WHJ; Louwman MWJ; Piersma D; van Rijn RS; Suijkerbuijk KPM; Ten Tije AJ; Vreugdenhil G; Wouters MWJM; van Zeijl M; Haanen JBAG; Uyl-de Groot CA
    Anticancer Drugs; 2018 Jul; 29(6):579-588. PubMed ID: 29634490
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Real-world treatment patterns and outcomes among metastatic cutaneous melanoma patients treated with ipilimumab.
    Mohr P; Ascierto P; Arance A; McArthur G; Hernaez A; Kaskel P; Shinde R; Stevinson K
    J Eur Acad Dermatol Venereol; 2018 Jun; 32(6):962-971. PubMed ID: 29044660
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hospitalization and emergency department utilization in patients with advanced melanoma receiving pembrolizumab versus ipilimumab plus nivolumab in US academic centers.
    Joseph RW; Shillington AC; Lee TA; Macahilig CP; Diede SJ; Dave V; Harshaw Q; Scherrer E; Liu FX
    J Med Econ; 2020 Feb; 23(2):132-138. PubMed ID: 31750751
    [No Abstract]   [Full Text] [Related]  

  • 5. Case Report: Encephalitis, with Brainstem Involvement, Following Checkpoint Inhibitor Therapy in Metastatic Melanoma.
    Bossart S; Thurneysen S; Rushing E; Frontzek K; Leske H; Mihic-Probst D; Nagel HW; Mangana J; Goldinger SM; Dummer R
    Oncologist; 2017 Jun; 22(6):749-753. PubMed ID: 28559410
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Health Care Resource Utilization and Costs in First-Line Treatments for Patients with Metastatic Melanoma in the United States.
    Klink AJ; Chmielowski B; Feinberg B; Ahsan S; Nero D; Liu FX
    J Manag Care Spec Pharm; 2019 Aug; 25(8):869-877. PubMed ID: 30945965
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Costs, resource utilization, and treatment patterns for patients with metastatic melanoma in a commercially insured setting.
    Toy EL; Vekeman F; Lewis MC; Oglesby AK; Duh MS
    Curr Med Res Opin; 2015 Aug; 31(8):1561-72. PubMed ID: 26086578
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Economic impact of healthcare resource utilisation patterns among patients diagnosed with advanced melanoma in the United Kingdom, Italy, and France: results from a retrospective, longitudinal survey (MELODY study).
    Johnston K; Levy AR; Lorigan P; Maio M; Lebbe C; Middleton M; Testori A; Bédane C; Konto C; Dueymes A; Sbarigia U; van Baardewijk M
    Eur J Cancer; 2012 Sep; 48(14):2175-82. PubMed ID: 22480965
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Real-world, population-based cohort study of toxicity and resource utilization of second-line ipilimumab for metastatic melanoma in Ontario, Canada.
    Dai WF; Beca J; Croxford R; Isaranuwatchai W; Menjak IB; Petrella TM; Mittmann N; Earle CC; Gavura S; Mercer RE; Hanna TP; Chan KKW
    Int J Cancer; 2021 Apr; 148(8):1910-1918. PubMed ID: 33105030
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Health Care Utilization and Costs Associated With Systemic First-Line Metastatic Melanoma Therapies in the United States.
    van Boemmel-Wegmann S; Brown JD; Diaby V; Huo J; Silver N; Park H
    JCO Oncol Pract; 2022 Jan; 18(1):e163-e174. PubMed ID: 34228489
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Durable Response of Metastatic Squamous Cell Carcinoma of the Skin to Ipilimumab Immunotherapy.
    Day F; Kumar M; Fenton L; Gedye C
    J Immunother; 2017 Jan; 40(1):36-38. PubMed ID: 27684455
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sequential treatment approaches in  the management of BRAF wild-type advanced melanoma: a cost-effectiveness analysis.
    Tarhini A; Benedict A; McDermott D; Rao S; Ambavane A; Gupte-Singh K; Sabater J; Ritchings C; Aponte-Ribero V; Regan MM; Atkins M
    Immunotherapy; 2018 Oct; 10(14):1241-1252. PubMed ID: 30175642
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Real-world treatment practice in patients with advanced melanoma in the era before ipilimumab: results from the IMAGE study.
    Middleton MR; Dalle S; Claveau J; Mut P; Hallmeyer S; Plantin P; Highley M; Kotapati S; Le TK; Brokaw J; Abernethy AP
    Cancer Med; 2016 Jul; 5(7):1436-43. PubMed ID: 27118102
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Health care resource use among patients with advanced non-small cell lung cancer: the PIvOTAL retrospective observational study.
    Lee DH; Isobe H; Wirtz H; Aleixo SB; Parente P; de Marinis F; Huang M; Arunachalam A; Kothari S; Cao X; Donnini N; Woodgate AM; de Castro J
    BMC Health Serv Res; 2018 Mar; 18(1):147. PubMed ID: 29490654
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical activity of ipilimumab for metastatic uveal melanoma: a retrospective review of the Dana-Farber Cancer Institute, Massachusetts General Hospital, Memorial Sloan-Kettering Cancer Center, and University Hospital of Lausanne experience.
    Luke JJ; Callahan MK; Postow MA; Romano E; Ramaiya N; Bluth M; Giobbie-Hurder A; Lawrence DP; Ibrahim N; Ott PA; Flaherty KT; Sullivan RJ; Harding JJ; D'Angelo S; Dickson M; Schwartz GK; Chapman PB; Wolchok JD; Hodi FS; Carvajal RD
    Cancer; 2013 Oct; 119(20):3687-95. PubMed ID: 23913718
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association of Pembrolizumab With Tumor Response and Survival Among Patients With Advanced Melanoma.
    Ribas A; Hamid O; Daud A; Hodi FS; Wolchok JD; Kefford R; Joshua AM; Patnaik A; Hwu WJ; Weber JS; Gangadhar TC; Hersey P; Dronca R; Joseph RW; Zarour H; Chmielowski B; Lawrence DP; Algazi A; Rizvi NA; Hoffner B; Mateus C; Gergich K; Lindia JA; Giannotti M; Li XN; Ebbinghaus S; Kang SP; Robert C
    JAMA; 2016 Apr; 315(15):1600-9. PubMed ID: 27092830
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of commonly used chronic medications on the outcomes of ipilimumab therapy in patients with metastatic melanoma.
    Failing JJ; Finnes HD; Kottschade LA; Allred JB; Markovic SN
    Melanoma Res; 2016 Dec; 26(6):609-615. PubMed ID: 27603551
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Economic and health care resource utilization burden of central nervous system metastases in patients with metastatic melanoma.
    Tawbi H; Bartley K; Seetasith A; Kent M; Lee J; Burton E; Haydu L; McKenna E
    J Manag Care Spec Pharm; 2022 Mar; 28(3):342-353. PubMed ID: 35199578
    [No Abstract]   [Full Text] [Related]  

  • 19. Ipilimumab in 2nd line treatment of patients with advanced melanoma: a cost-effectiveness analysis.
    Barzey V; Atkins MB; Garrison LP; Asukai Y; Kotapati S; Penrod JR
    J Med Econ; 2013; 16(2):202-12. PubMed ID: 23057750
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost and economic burden of adverse events associated with metastatic melanoma treatments in five countries.
    Vouk K; Benter U; Amonkar MM; Marocco A; Stapelkamp C; Pfersch S; Benjamin L
    J Med Econ; 2016 Sep; 19(9):900-12. PubMed ID: 27123564
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.